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Abstract
The purpose of this study was to conduct an interlaboratory ring-study, with six partners 
(academic and industrial), investigating the measurement of intrinsic dissolution rate (IDR) 
using surface dissolution imaging (SDI) equipment.   Measurement of IDR is important in 
pharmaceutical research as it provides characterising information on drugs and their 
formulations.   This work allowed us to assess the SDI’s interlaboratory performance for 
measuring IDR using a defined standard operating procedure (see supporting information) 
and six drugs assigned as low (tadalafil, bromocriptine mesylate), medium (carvedilol, 
indomethacin) and high (ibuprofen, valsartan) solubility compounds.   Fasted State Simulated 
Intestinal Fluid (FaSSIF) and blank FaSSIF (without sodium taurocholate and lecithin) (pH 
6.5) were used as media.   Using the standardised protocol an IDR value was obtained for all 
compounds and the results show that the overall IDR rank order matched the solubility rank 
order.   Interlaboratory variability was also examined and it was observed that the variability 
for lower solubility compounds was higher, coefficient of variation >50%, than for 
intermediate and high solubility compounds, with the exception of indomethacin in FaSSIF 
medium.   Inter laboratory variability is a useful descriptor for understanding the robustness 
of the protocol and the system variability.   On comparison to another published small-scale 
IDR study the rank ordering with respect to dissolution rate is identical except for the high 
solubility compounds.   This results indicates that the SDI robustly measures IDR however, 
no recommendation on the use of one small scale method over the other is made.   
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1 Introduction
The most convenient and frequent way of administering drugs is via the oral route (1). 
Generally, dosage forms consist of an active pharmaceutical ingredient (API) and excipients, 
which help to ensure the drug reaches its site of action, prevent unwanted decomposition and 
in some cases controlling release. To exert an effect the drug must: dissolve in the aqueous 
environment of the gastrointestinal tract; remain in solution to be available for absorption; 
and be sufficiently lipophilic to be absorbed. The key drug attributes, solubility and 
permeability, are succinctly classified in the widely used Biopharmaceutics Classification 
System (BCS) (2).
1.1 Solubility and Dissolution
Drug solubility and dissolution are interrelated parameters important for bioavailability and 
can be affected by internal as well as external factors. Internal factors include the drug’s 
chemical structure, particle size and crystal form as well as any ionisable groups in the 
molecule. The external factors include the gastrointestinal (GI) tract environment and 
behaviour. The GI tract environment for example contains bile salts, phospholipids, fatty 
acids and proteins in different concentrations throughout the digestive tract and these have an 
impact on drug behaviour. Solubilisers such as bile salts and lecithin for example can 
increase solubility of lipophilic drugs (3, 4). In addition the GI tract luminal content viscosity, 
mixing, and flow pattern also vary (5) and pH varies between the stomach (pH 1.5-4) and 
intestine (pH 5-7) (6). Depending upon the drug’s pKa ionisation and solubility will therefore 
vary and the use of salt forms may result in completely different drug solubilities and 
dissolution rates in GI tract fluids than in pure water (3, 7, 8). Biorelevant media such as 
FaSSIF (Fasted Stated Simulated Intestinal Fluid) are commonly used to more accurately 
mimic in vivo conditions, resulting in better predictions overall (9). These media have 
frequently been used to mimic human intestinal fluids for greater biorelevance in solubility 
and dissolution experiments (3, 10, 11).
1.2 Intrinsic Dissolution Rate (IDR)
Dissolution is an important in vitro test, as it provides crucial information on the release of 
the API from a formulated product which can then be used to guide formulation 
development, and ultimately, provide assurance of reliable drug release in humans. The 
intrinsic dissolution rate (IDR) is defined as the amount of drug dissolved per unit time per 
unit area and is therefore expressed as a rate, in contrast to the thermodynamic equilibrium 
reported by solubility data. IDR determination can be used in the selection of optimal forms 
and versions (e.g. salts), and can improve prediction of drug behaviour in the dynamic 
situation found in the GI tract (12). In addition, studies carried out using disc IDR were 
reported to be a simple, convenient and feasible way to determine BCS solubility class (13). 
Yu et al. showed that IDR values determined using Wood’s apparatus can be used to classify 
compounds as either high or low solubility under different pH conditions. The classification 
matched the BCS system for solubility based on an IDR cut-off of 0.1 mg/min/cm2 (13).
Apparatus for IDR is described by pharmacopoeias and includes the rotating disk system (or 
Wood’s apparatus). This is a modified USP I/II set up whereby a disc of API with a known 
surface area is rotated in a dissolution vessel and the concentration at set time points 
measured. IDR is expressed by the Nernst-Brunner adaptation of the Noyes Whitney equation 
as (14) 
  Equation 1
𝑑𝐶
𝑑𝑡 = 𝐷𝐴𝑉ℎ(𝐶𝑠 ― 𝐶𝑏)
Where C is the concentration of API dissolved (mg/mL), t is the sampling time (min), D is 
the diffusion coefficient (cm2/min), A is the surface area (cm2), V is the volume of the 
medium (mL), h is the boundary layer thickness at interface between drug solid and solution 
(cm), Cs and Cb are the concentrations at saturation (present in the boundary layer) and in the 
bulk solution respectively (mg/mL).
Diffusion coefficient of an API is affected by properties of the dissolution media, and in 
biorelevant media, the diffusion coefficient is a function of both the diffusion of the unbound 
API and the diffusion of the API within micelles (15, 16).Deff = Dmonofmono + Daggfagg Equation 2
Where Deff is the effective diffusion coefficient, Dmono and Dagg is the diffusion coefficient of 
the unbound (monomer) and micelle bound (aggregate) API respectively (cm2/min), and f is 
the fraction of the monomer and aggregated API. 
The work here will focus on the IDR of compounds in two media (FaSSIF and blank 
FaSSIF). IDR is related to dissolution rate equation and is a function of area whereby: 
Equation 3𝐼𝐷𝑅 = 𝑑𝑐𝑑𝑡 ∗ 𝑉𝐴 = 𝐷ℎ(𝐶𝑠 ― 𝐶𝑏)
1.3 Small Scale Intrinsic Dissolution Apparatus
The use of Wood’s apparatus to determine IDR is rarely feasible during early development 
due to the amount of API required. Miniaturised methods have therefore been developed 
which need only minimal drug, and utilise small volume vials (rotating and stationary disc 
systems), 96-well plates, flow through cells, and optical microscopy (17-22). An example of 
a system utilising small volume vials (up to 20 mL) is the Pion µDISS Profiler™, which can 
measure disc, powder and controlled suspensions (23-25). Standardised procedures for IDR 
determination using the μDISS Profiler™ were proposed based on an interlaboratory study 
(26) as part of the IMI OrBiTo collaboration (27, 28). The ability of the μDISS Profiler™ to 
use minimal amounts of API and the ease of use makes it an attractive option for IDR 
determination in early preformulation work. In this study, further interlaboratory comparisons 
were conducted to evaluate an alternative small-scale IDR method, which combines IDR 
measurement with UV imaging of the dissolution process.
The IDR measurement technique investigated in this study utilises the Sirius Surface 
Dissolution Imaging (SDI) system (29) whuich allows real-time monitoring of dissolution 
and release from the surface of a small compressed disc of drug. Dissolution studies 
performed over 5-30 min at specific flow rates allows determinations of IDRs, surface 
concentrations and the cumulative amount of drug dissolved using UV imaging. Moreover, 
videos can be generated for visual examination of the dissolution process (30-35). Examples 
of IDR studies using UV imaging include comparisons between different forms of drugs and 
their salts/hydrates, and between micronised and nonmicronised material. Form changes can 
also be studied with the use of simultaneous Raman spectroscopy. The system has also been 
used to determine diffusion coefficients and solubility (35-38).
The SDI works by filtering light through a bandpass filter, followed by a diffuser to refocus 
on a specific UV wavelength. The light then passes through a lens to collimate it and is 
presented to the front of a quartz flow cell containing the sample. The detector readout is 
passed to the computer (37, 39, 40), where the software analyses 3 zones from the image 
(Figure1).
Figure 1. Image from the SDI analysis software while investigating valsartan dissolution in 
phosphate buffer. Picture from one partner taken from analysis software. Within the software, 
the x-axis is the horizontal axis and the y-axis is the vertical axis, background absorbance 
zone (medium only) is the reference zone to account for variations in media absorbance, the 
surface absorbance zone measures the concentration above the API compact surface, IDR 
absorbance zone measures the concentration at the outlet which is used for IDR calculations 
by the software.
A published convection dissolution model, developed by Nelson and Shah (41, 42), which 
has been applied to both static and flow through systems and accounts for changes in velocity 
and concentration gradients above the surface has been applied to the SDI. For circular 
compacts, the dissolution rate (R) is represented by:
Equation 4R = 2.157.𝐷2/3.𝑐0.α1/3.𝑟5/3
Where D is the diffusivity (cm2/min), c0 is the solubility (mg/mL), r is the compact radius 
(cm), and α is the shear rate in boundary layer
Equation 5𝛼 = 6𝑄𝐻2𝑊
Where Q is the volumetric flow rate (mL), H is the height of channel (cm), W is the width of 
channel (cm). Using the SDI data analysis software the IDR is calculated from (43):
 Equation 6𝐼𝐷𝑅 = ∑𝐻2𝑧 = 0(𝑣𝑧𝑀𝑐𝑧W𝛥𝑧)𝑆
 Equation 7𝑣z = 3𝑄2𝐻𝑊 ∗ (1 ― ((2𝑧 ― 𝐻)2𝐻2 ))
Where z is the height above z-origin (cm – variable, set by analyst), vz is the velocity at z, M 
is the molecular weight (Da), cz is the concentration at z (μg/mL), W is the width of flow cell 
channel (cm), Δz is the effective pixel height (cm), S is the surface area of sample (cm2), H is 
the height of flow cell channel in observation region (cm), Q = volumetric flow rate 
(mL/min). 
The purpose of this work was to conduct an interlaboratory ring study using the Sirius SDI 
apparatus to measure IDR. To this end the variability of IDR values measured at different 
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sites was assessed. An investigation into molar extinction coefficient (MEC) values and 
variability was also conducted. A standardised procedure for compressing the API powders 
into compacts was utilised and each partner used a pre-defined protocol for each of the six 
APIs. The IDR work was carried out over six partner sites (two academic and four industrial) 
using the same batch for each of the compounds unless specified. This will provide 
information on the robustness of the SDI system for IDR measurement when sites use a 
standard method, providing a level of confidence in the data generated. A comparison 
between the μDISS Profiler™ system and SDI results and variability was carried out to 
provide information on the usefulness of the flow through imaged IDR data (26).
Andersson et al. described boundaries for high, intermediate and low solubility APIs whereby 
disc and/or powder IDR determination can be used (26). The six compounds chosen for this 
study were: two high solubility APIs (solubility > 1mg/mL – valsartan and ibuprofen), two 
intermediate solubility APIs (100µg/mL < solubility < 1mg/mL – carvedilol and 
indomethacin), and two low solubility APIs (solubility < 100µg/mL – tadalafil and 
bromocriptine mesylate) (Table 1). The drugs were also selected to provide continuity to the 
interlaboratory dissolution studies performed with the μDISS Profiler™ (26).
2 Material and Methods
2.1 Materials
Valsartan, ibuprofen, carvedilol, tadalafil, indomethacin and bromocriptine mesylate (Table 
1) were kindly provided through the Orbito consortium with the exception of site number 6 
who sourced ibuprofen separately due to stock availability issues. FaSSIF powder was 
purchased through Biorelevant.com. Sodium hydroxide (NaOH), monobasic sodium 
phosphate monohydrate (NaH2PO4·H2O) and sodium chloride (NaCl) were purchased from 
Sigma Aldrich. 
Table 1. Physicochemical properties of the 6 APIs investigated.
API Classification MW/FW pKa LogP LogD 
at 
pH6.5 
Sapp 
FaSSIF/ 
Sapp 
blank 
FaSSIF
Solubility 
(μg/mL)*
Ref†
Bromocriptine 
mesylate
Base 654.6/750.7 4.9 2.909 2.899 14.275 60.4 (Sapp 
FaSSIF) ‡
3 (Sapp pH 6.5) 
‡∆
(26, 
44)
Carvedilol Base 406.5 7.9 2.784 1.384 2.738 136 (FaSSIF)
51.6 (Blank 
FaSSIF)
(45, 
46)
Ibuprofen Acid 206.3 4.4 2.904 0.804 1.146 1560 
(FaSSIF)7935 
(pH 6.5)
(47-
49)
Indomethacin Acid 357.8 4.5 4.30 2.3 435.8 
(FaSSIF)
306.98 (Blank 
FaSSIF)
(50)
Tadalafil Base 389.4 0.85 
(predicted)
2.61 2.61 0.997 2.5 (Sapp 
FaSSIF) ‡
(26, 
51)
2 (pH not 
specified)
Valsartan Acid 435.5
4.7
3.942 2.142 951.609 
(FaSSIF)
594 – 628 
(Blank 
FaSSIF)
(26, 
52)
† Other sources for MW/FW and pKa were pubchem.ncbi.nlm.nih.gov and 
www.druginfosys.com, drugs@ FDA: FDA approved drug products.
‡ Sapp is the apparent solubility based on maximum concentrations from μDISS dissolution 
experiments.
∆ The solubility value for bromocriptine mesylate was recorded after more than 400 minutes 
post exposure to the medium and there was evidence that the salt had disproportionated to the 
parent.
* All solubility measurements were performed at 37oC.
2.2 Methods
2.2.1 FaSSIF buffer and media preparation
FaSSIF and blank FaSSIF (both version1) were prepared using the instructions supplied 
through Biorelevant.com (53), based on the composition proposed by Galia et al. (54). Blank 
FaSSIF was prepared in the same way as FaSSIF with the exclusion of the FaSSIF powder. 
2.2.2 Equipment
Sirius SDI equipment (Sirius Analytical, East Sussex,UK) was used for IDR assays. SDI data 
collection and analysis software (version 1.8.50814) was used to analyse the runs and values.
2.2.3 Solution preparation
Stock solutions of the APIs in FaSSIF and blank FaSSIF were prepared. For higher solubility 
drugs (ibuprofen, valsartan, indomethacin and carvedilol), a minimum five-point calibration 
curve (absorbance (mAU) versus concentration (mM)) was created. Due to the low solubility 
for some APIs, the mean molar extinction coefficient (MEC) of three solutions of similar 
concentration was calculated. Up to 10% V/V methanol was added to the solution as a co-
solvent to increase solubility. Sonication was used where required to aid dissolution. In the 
experiments, where methanol was added, and/or the solutions sonicated, the medium used for 
blanking the system was treated in the same manner.
2.2.4 Compact preparation
Approximately 4mg of API was weighed into the micropress and for compressed at 80 cN.m 
for 5 min using a calibrated torque wrench. Compacts were prepared, where possible, just 
before measurement and the compact’s surface area, assuming a flat surface, is 0.00314 cm2.
2.2.5 Molar Extinction Coefficient
The Molar Extinction Coefficient (MEC) was determined at each site using the following 
methods at the same wavelength used for IDR work
The SDI pump and data collection software was programmed to run for 10 min at 0.5 
mL/min. The system was blanked with buffer and when prompted a syringe containing the 
drug calibration solution (4mL) was loaded and pumped through the flow cell at 2 mL/min, 
followed by resetting the pump to 0.5 mL/min. Each calibration concentration was run 
individually.
Two sites (sites 2 and 4) used the following alternative method. The data collection software 
was setup to run continuously for 40 min. The pump was operated manually (in withdraw 
mode) to flow standard solutions through the dissolution cell at a flow rate of 1 mL/min for 4 
min at each concentration. Blank medium was flushed through the dissolution cell for 4 min 
before and after the standard solutions to detect baseline drifts. The absorbance values were 
read and used for construction of the calibration curve.
2.2.6 MEC data analysis
Where a calibration curve of absorbance versus concentration was utilised, a regression line 
was drawn through the plot and assessed to ensure linearity was maintained at all 
concentrations and the MEC was calculated by dividing the slope of the line by the path-
length. Where solutions of similar concentration were used, the mean MEC of the three 
solutions was calculated and used for IDR work. The five-point calibration was the preferred 
method but the alternative method was used if solubility was too low (tadalafil and 
bromocriptine). Each site determined and used their own MECs and comparisons between 
sites was carried out by calculating the mean MEC. 
2.2.7 IDR
The SDI flow cell temperature was set to 37oC and the appropriate wavelength filter installed. 
If air bubbles in the flow cell were problematic, the media could be pre-warmed to minimise 
the risk of air bubble appearance. The pump settings on the data collections software were 
adjusted as detailed in Table 2. The wavelengths and flow rates were optimised at one site 
before the study. Optimisation was carried out to maintain as high a concentration within IDR 
zone as possible (whilst remaining in the linear range). The same flow rate could not be used 
for all compounds due to the differences in solubility.
Partners were provided with defined methods to follow for IDR determination. All sites were 
requested to follow the standardised procedure for compact preparation, flow rate and 
wavelength conditions, and for data analysis.
Table 2. The wavelength, flow rate and run time for each of the six APIs under investigation.
API Wavelength (nm) Flow Rate (mL/min) Run Time (min)
Bromocriptine Mesylate 254 0.1 20
Carvedilol 280 0.2 20 
Ibuprofen 254 0.2 20 
Indomethacin 254 0.5 20 
Tadalafil 280 0.1 40
Valsartan 254 0.8 20
2.2.8 IDR determination
The system was previewed and blanked, then the sample was loaded into the cell insert when 
prompted by the instrument. The system was flushed with media three times at the elevated 
angle to remove air bubbles, during the third flush the cartridge was lowered to the horizontal 
position and data collection restarted. The above IDR steps were repeated until six acceptable 
results were obtained. Results were deemed unacceptable if one or more of the following 
exclusion criteria were met: negative IDR values, air bubbles in the system, and where the 
RSD values over 60 s intervals exceeded 10%. These features indicated a possible failure of 
the run and/or compact formation.
2.2.9 IDR data analysis
The MEC, molecular weight and compact weight were entered into the data analysis 
software. The z-origin was adjusted so that there was no increase in absorbance after the first 
point, this was visualised in concentration/absorption profile tab of the software. 
The mean and standard deviation of each compact were calculated from the data points 
collected 6 to 20 min after initiation of the dissolution experiment (21 to 40 min for tadalafil). 
Early work by one partner investigated when the IDRs measurements should be taken, at 
these points it is expected that the curves would be linear, and due to continuous flow sink 
conditions are assumed. Once six replicates were accepted, the mean and standard deviation 
were calculated using the mean IDR from each run. If an IDR for one compact exceeded 1.64 
standard deviations from the overall mean (90% of normally distributed results should fall 
within this range), then the result was excluded and repeated. Outliers could be excluded as 
they do not signify normal IDR for the compounds. This could be due to issues with compact 
formation or media blanking. A maximum of two runs could be excluded in this way. For the 
final included data set the mean, standard deviation, RSD, median and quartiles was 
calculated for comparison.
Between site comparisons were conducted on mean IDRs for each site. From these data the 
overall mean IDRs, standard deviations and RSDs were calculated.
3 Results and Discussion
The variability associated with dissolution testing experiments performed using the SDI 
systems has not previously been studied. Six compounds were selected based on initial work 
by one partner. 
One partner (site 6) had technical difficulties with their SDI system and the team were not 
able to complete the experimental work in house. In an effort to provide a full data set, the 
syringe pump, cartridge and tools from the site’s system were transferred to another site and 
used with a detector and heating block from another SDI system. A crossover compound 
(indomethacin, with the blank FaSSIF medium) was also examined. These experiments were 
analysed and have been kept separate from the original site 6 data and have been designated 
as site 7 in results. Indomethacin in blank FaSSIF was selected as all other sites had data for 
this API/medium combination and there was sufficient quantity of the API to allow a 
duplicate run including MEC to be completed. It was originally intended that this data could 
be used to provide a complete dataset for site 6, however this was not possible (see IDR 
results).
3.1 MEC
Each site measured MECs to take into account possible differences with respect to system 
performance, including lamp age. A single MEC used for all sites was not appropriate as the 
UV lamps are not replaceable and the systems used were of varying ages, with differences in 
the number of lamp hours. Additionally, the bandpass filters were different and differences in 
UV transmission between the filters is possible. During analysis, path length was not altered, 
the equipment has a standard path length of 0.4 cm.
The mean MECs were used to give an indication of the variability between systems in terms 
of detector performance. The variability of carvedilol in FaSSIF was the greatest at around 
45% RSD (with a range of 4900 to 16000). The variability of carvedilol in blank FaSSIF was 
also high at around 37% RSD, with the MEC at one site around half the value of the highest 
(see Supplementary Material - Table 5). See Figure 2 for the MEC determined at each site. 
One reason for the higher variability in tadalafil and carvedilol may be due to their relatively 
low solubility compared to other compounds in this study that have a higher solubility. 
Where the calibration curve method was used, absorbance vs concentration was shown to be 
linear across the concentration range. There is no evidence that the different methods for 
MEC determination affect the results since MEC values at sites which used method 2 shows 
no pattern of high or low values. As the work was investigational it was assumed that the 
stated concentrations were accurate and no orthogonal determination of the solution 
concentrations was carried out.
Figure 2. MEC values determined in dissolution media by UV imaging at each site. Val – 
valsartan, Ibu – ibuprofen, Car – carvedilol, Ind – indomethacin, Tad – tadalafil, Bro – 
bromocriptine mesylate, FaS – FaSSIF, Bl FaS – blank FaSSIF. Insert is close up of 
ibuprofen results for clarity. Error bars on mean marker represent 1 standard deviation, where 
not visible, the error bars do not extend beyond the symbol. Mean MEC was calculated as a 
mean of individual sites as some were calculated from a calibration curve.
3.2 IDR
IDR can provide useful information in early drug development, especially small-scale 
methods where only a small quantity is required. It can be used to provide information on the 
performance of different API forms and salts to guide selection. The overall mean IDR for 
each API in the different media can be found in Table 3. The highest solubility APIs had the 
highest IDR values. The intermediate solubility drug substances (carvedilol and 
indomethacin) had intermediate IDR values while tadalafil and bromocriptine mesylate had 
the lowest values.
Table 3. Overall mean IDR values for each drug in both media. Individual site means also detailed.
Drug Media Overall Mean (μg/min/cm2) ∆
(SD)
[RSD]
Site Site Mean (μg/min/cm2) 
(SD)
RSD n† Total  
runs ‡§
Site 1 2.0 (0.90) 45% 6 8
Site 2 1.7 (0.40) 24% 6 7
Site 3 3.1 (0.74) 24% 6 7
Site 4 4.0 (2.4) 60% 6 8
Site 5 0.43 (0.18) 42% 6 15
FaSSIF
3.4
(2.7)
[82%]
Site 6 8.2 (4.4) 54% 4 7
Site 3 6.4 (6.1) 96% 6 6
Site 4 2.1 (2.0) 94% 6 9
Bromocriptine Mesylate
Blank FaSSIF
2.2
(2.7)
[20%] Site 6 4.4 (4.7) 110% 6 8
Site 1 3.7 (0.78) 21% 6 6
Site 2 10 (1.5) 14% 6 8
Site 3 4.3 (1.3) 30% 6 7
Site 4 5.9 (2.3) 39% 6 13
FaSSIF
7.1
(4.2)
[59%]
Site 7 11 (5.8) 51% 6 6
Site 1 4.0 (1.8) 45% 6 6
Site 2 3.6 (0.41) 11% 6 8
Site 3 2.0 (0.51) 25% 6 12
Site 4 6.4 (2.9) 46% 6 12
Carvedilol
Blank FaSSIF
3.6
(2.3)
[65%]
Site 7 1.4 (0.88) 62% 5 6
Site 1 66 (13) 20% 6 8
Site 2 89 (17) 19% 6 8
Site 3 89 (16) 18% 6 10
Site 4 60 (8.4) 14% 6 7
Site 5 47 (8.3) 18% 6 7
FaSSIF
75
(24)
[33%]
Site 6 110 (22) 20% 4 7
Site 1 55 (15) 27% 6 6
Site 2 57 (16) 28% 6 12
Site 3 57 (13) 22% 6 8
Ibuprofen
Blank FaSSIF
66
(30)
[46%] Site 4 73 (7.1) 9.7% 6 7
Site 5 50 (17) 34% 6 8
Site 6 120 (52) 42% 4 6
Site 1 8.9 (0.90) 10% 6 7
Site 2 22 (4.1) 19% 6 6
Site 3 19 (5.9) 32% 6 8
Site 4 15 (2.2) 15% 6 10
Site 5 7.9 (1.5) 19% 6 6
FaSSIF
19
(15)
[79%]
Site 6 47 (22) 46% 5 6
Site 1 8.4 (0.86) 10% 6 8
Site 2 16 (2.3) 15% 6 9
Site 3 16 (7.5) 47% 6 10
Site 4 15 (2.5) 16% 6 10
Site 5 8.8 (1.3) 15% 6 7
Site 6 13 (5.6) 44% 2 6
Indomethacin
Blank FaSSIF
13
(4.8)
[38%]
Site 7 12 (7.4) 63% 2 3
Site 1 0.80 (0.38) 47% 6 6
Site 2 0.33 (0.049) 15% 6 9
Site 3 1.5 (0.60) 39% 6 6
Site 4 6.6 (3.8) 59% 6 7
Site 5 1.5 (0.50) 34% 6 8
FaSSIF
2.1
(2.7)
[130%]
Site 6 2.1 (2.3) 110% 5 7
Site 3 0.62 (0.28) 45% 6 8
Site 4 7.4 (0.59) 7.9% 6 7
Tadalafil
Blank FaSSIF
2.9
(3.3)
[120%] Site 6 0.59 (0.28) 47% 6 8
Site 1 25 (3.8) 16% 6 6
Site 2 60 (8.9) 15% 6 9
Site 3 75 (11) 15% 6 6
Site 4 50 (15) 30% 6 7
Site 5 45 (7.0) 16% 6 11
FaSSIF
48
(21)
[43%]
Site 7 20 (12) 59% 3 4
Site 1 34 (5.6) 16% 6 7
Site 2 51 (3.1) 6.0% 6 9
Valsartan
Blank FaSSIF
37
(16)
[45%] Site 3 18 (6.6) 37% 6 10
Site 4 52 (5.6) 11% 6 6
Site 5 44 (7.4) 17% 6 6
Site 6 37 (3.8) 10% 2 3
Site 7 4.2 (1.8) 42% 3 6
∆ overall mean calculated from all replicates from all sites.
† number of replicates per site.
§ Site 4 used some compounds for training purposes (increasing the number of runs)
‡ number of runs per site.
The equations for dissolution rate and IDR (Equations 1, 3 and 4) assume that the 
concentration at the API surface is the same as the solubility in the bulk medium. This is 
however variable depending on the microenvironment surrounding the surface. As an 
ionisable compound dissolves, the pH in the static layer in contact with the compound can be 
increased or decreased from the bulk for bases and acids respectively (55, 56). Where the 
pKa is close to the pH of the bulk medium, there is the possibility that pH changes can affect 
the solubility within the boundary layer at the compact surface. While this is difficult to 
overcome, awareness of the differences in solubility is important. For all APIs studied here, 
with the exception of tadalafil, there is a risk that the surface solubility is lower than the bulk 
due to pH changes thus decreasing the IDR. The compact surface pH was not determined in 
this study and therefore the possible impact of this effect has not been investigated. Each 
compound was investigated with a set flow rate, changes to this flow rate may alter the 
microenvironment at the compact surface and could be applied to study this phenomenon.
Buffer capacity and buffer type has also been shown to affect the dissolution rate. Krieg et al. 
demonstrated for ibuprofen and indomethacin that changing the buffer capacity will result in 
an increase in dissolution rate without a change in bulk pH (55). It is not only the buffer 
capacity which can affect dissolution since in the same study Krieg et al. showed that 
bicarbonate and phosphate buffers with the same capacity, show different IDRs (55). The 
work conducted here was carried out using a phosphate buffer with a set buffer capacity 
based on the recipe provided Biorelevant, therefore the results here can be compared between 
sites.
Site 6 utilised a different ibuprofen supply and to assess this internal studies at site 1 (not 
published) investigated the difference in IDR between four ibuprofen sources. It was found 
that the IDR of the OrBiTo supplied ibuprofen was statistically higher than commercial 
supplies from Sigma-Aldrich and BASF. While this may have affected measured IDR values, 
it was not sufficient to affect the overall rank order of the compounds.
The variability of the IDR results observed here for all replicates (33% to 130%) is similar to 
the μDISS IDR disc results from the interlaboratory study described earlier (26) where the 
coefficient of variation observed ranged from around 55% to 110%. These variabilities show 
that the SDI has a similar robustness to the μDISS. Robust intersite performance is important, 
if during the development of a compound it may be analysed using different systems. It is 
beneficial to have an understanding on potential differences between different systems in use, 
giving confidence to the results achieved.
From Table 3, the IDR for indomethacin in blank FaSSIF is similar between sites 6 and 7, 
however, valsartan had a lower IDR than expected in blank FaSSIF. It was not clear why this 
was the case. As a result site 7 was treated independently to site 6.
Due to the unavailability of the raw data; the indomethacin IDR values were recalculated 
post-analysis at site 7 using the correct MEC value according to Beer-Lambert Law. 
3.2.1 Results in rank order of mean IDR
Data across the sites has been tabulated in overall rank order of mean IDR for both FaSSIF 
and blank FaSSIF. In FaSSIF media, the overall rank order of mean IDR was ibuprofen > 
valsartan > indomethacin > carvedilol > bromocriptine mesylate > tadalafil. This rank order 
follows the rank order of solubility. Only sites which were able to complete all six 
compounds were included in this analysis. The rank order was not maintained at site 4 
compared to the overall sites 1-3 rank order, with tadalafil, carvedilol, and bromocriptine 
mesylate having a different order (Figure 3).
At site 5, the rank order was ibuprofen > valsartan > indomethacin > tadalafil > 
bromocriptine mesylate. At site 6, the rank order was ibuprofen > indomethacin > 
bromocriptine mesylate > tadalafil. At site 7 only two compounds were tested in FaSSIF, the 
rank order was as expected for these compounds based on the grouped rank order.
Differences between site rank order are not wholly unexpected in biorelevant media as 
variations can be observed in the micelles (15).
 
Figure 3. Rank order IDR of compounds in FaSSIF. Only sites which completed all 6 
compounds in FaSSIF are included. ( ) Site 1, ( ) Site 2, ( ) Site 3, ( ) Site 4, ( ) group 
rank order. Ibu – ibuprofen, Val – valsartan, Ind – indomethacin, Car – carvedilol, Bro – 
bromocriptine mesylate, Tad – tadalafil.
The work with blank FaSSIF was not planned to be carried out on tadalafil and bromocriptine 
mesylate due to their low solubility and they are therefore excluded from this analysis. The 
rank order was ibuprofen > valsartan > indomethacin > carvedilol (Figure 4) with the rank 
order maintained between the 4 sites which completed the four compounds. As above the 
rank order followed the rank order for solubility. 
The rank order of the high and intermediate compounds at sites 5 and 6 followed the same 
rank order. At site 7, however, valsartan had a lower IDR than expected and it was not clear 
why this was the case.
If we look at all six compounds it was observed that overall, bromocriptine mesylate showed 
greater IDR values than carvedilol. A number of factors affect dissolution rate, and lower 
solubility compounds having a faster rate of dissolution is not unexpected, which may be 
affecting the dissolution rate in the blank FaSSIF medium.
Figure 4. Rank order IDR of compounds in FaSSIF. Only sites which completed all moderate 
and high solubility compounds in FaSSIF are included. ( ) Site 1, ( ) Site 2, ( ) Site 3, ( ) 
Site 4, ( ) group rank order. Ibu – ibuprofen, Val – valsartan, Ind – indomethacin, Car – 
carvedilol.
Although the overall rank orders observed for FaSSIF was the same as solubility, it should 
not be assumed that solubility rank order directly translates into IDR rank order. This was the 
case for bromocriptine and carvedilol, in blank FaSSIF.
3.3 SDI versus μDISS
Five of the APIs studied here were also studied in the μDISS Profiler™ system, carvedilol 
was not included in the study by Andersson et al. and is not included in this part of the 
discussion (26). The study by Andersson et al. determined IDR on both API powder and 
compacted discs, only the disc IDRs will be discussed and the mean IDR comparisons can be 
found in Figure 5. Direct comparisons between the IDR values were not appropriate as the 
conditions were different between the methods. The rank order for the disc IDRs in FaSSIF 
for μDISS Profiler™ was valsartan > ibuprofen > indomethacin > bromocriptine mesylate > 
tadalafil (26). This differs from the rank order for the current SDI work: ibuprofen > valsartan 
> indomethacin > bromocriptine mesylate > tadalafil. The high solubility compounds have 
switched places but apart from that the order is identical. When the μDISS IDR is plotted 
against the SDI values a linear relationship was not observed, with an R2 value of 0.55. 
Valsartan appears to be an outlier in the data. When valsartan is excluded a linear relationship 
with an R2 value of 0.98 is observed. It is unclear whether valsartan IDR is over or under 
estimated in the μDISS or SDI respectively. One possibility for the results is due to valsartan 
being a high solubility, high UV absorbance compound, which could be affecting the IDR 
results measured in both studies. Further work is needed on high solubility, high absorbance 
compounds to allow that distinction to be made. Another possibility could be the differences 
in the compact microenvironments between the static and flow through systems. APIs will 
dissolve to saturation around the compact before diffusing into the bulk media, as the 
hydrodynamics of both static and flow through systems differ there could be an effect on 
IDR. The IDR values for the SDI and μDISS are expected to differ based on the differences 
between the systems. The SDI utilises a static compact where medium is passed over the 
compact at a set flow rate whereas the μDISS utilises a rotating compact. The method of 
detection varies between the two systems also. Where the SDI detects a single wavelength the 
μDISS detects across the spectrum and a range can be used. The quantitative performance of 
the UV imaging setup (SDI) with respect to determining dissolution rates has previously been 
assessed (57, 58). As with solubility, IDRs measured are affected by different measurement 
conditions and comparisons between different techniques should be qualitative. A 
comparison to Wood’s apparatus is recommended, ideally using the same batch of APIs used 
in this study, as well as running carvedilol using the same μDISS methods used by Andersson 
et al.(26). 
Figure 5. IDR comparison between SDI ring study and μDISS ring study. All results in FaSSIF 
at 37oC. ( ) Bromocriptine Mesylate, ( ) Ibuprofen, ( ) Indomethacin, ( ) Tadalafil, ( ) 
Valsartan
3.4 Single operator analysis
To investigate the variability introduced by different operators carrying out the analysis at 
multiple sites it was decided that one person would process the indomethacin data for all sites 
in both FaSSIF and blank FaSSIF media. Variability due to operator can occur due to 
inconsistencies in FaSSIF preparation as it is known that micelle size is particularly sensitive 
to the concentration of SIF used (15). Further source of variability between operators can 
occur with the placement of the z-origin in the analysis software. This origin determines the 
amount of absorption data included in IDR determinations. Operators were instructed on 
setting the origins within the software as part of the shared methods.
Raw data files from sites 1 to 6 were sent to a single operator for analysis, along with details 
of the indomethacin MEC in both FaSSIF and blank FaSSIF. Site 7 was excluded from the 
analysis as raw SDI files were not available. In FaSSIF medium, the single operator analysis 
improved the variability (Table 4) over all sites. When blank FaSSIF medium was used, 
single operator analysis did not reduce the observed variability.
While single operator analysis successfully reduced the variability of the mean IDR in 
FaSSIF, there was a lack of improvement in the lower variability blank FaSSIF analysis. The 
larger variability difference for FaSSIF could be narrowed down to site 6. If this site is 
excluded from the analysis then the site analysis mean reduced to 14 μg/min/cm2 with an 
RSD of 44%, which is similar to the single operator analysis. A reason for this deviation at 
one site was not determined but could be down to operator error. From this analysis it shows 
that following a standard protocol for IDR determination, which includes data analysis 
methods, reduces the variability from different interpretations for origin placement. 
Following a set protocol for both conducting the experiments and analysing the results will 
improve the intrasite comparisons between individuals using the same piece of equipment 
assuming the same medium is used. 
 
Table 4. Comparison of mean indomethacin IDR in FaSSIF and variability between different 
methods of analysis.
Site Analysis Single Operator Analysis
Mean IDR 
(μg/min/cm2) 19 14
FaSSIF
RSD 79% 44%
Mean IDR 
(μg/min/cm2) 13 13
Blank 
FaSSIF
RSD 38% 39%
Only one compound was chosen for single operator analysis to highlight the possible 
differences in user analysis. Although partners were provided guidance on analysis there may 
have been instances where this was deviated from. The object of the work here was to 
investigate the variability between sites, as a single user would not be present at each site in a 
real-world scenario the sites would only have internal data for comparisons. This analysis 
highlights the importance of defining the method of analysis to be used at a site to allow 
comparison between different compounds. It is suggested that all users at each site should be 
trained on the analysis protocol.
4 Conclusions
Disc IDRs were measured for all six compounds at most participating sites with reasons for 
not achieving universal coverage due to technical issues and lack of available API. The study 
has shown that, in general, rank order for overall mean IDR was similar to solubility rank 
order in both FaSSIF and blank FaSSIF. Variability between sites ranged between 33% and 
130%, and was highest for lower solubility compounds. This level of variability was similar 
to the variability observed between another interlaboratory small-scale IDR study (26).
The variability for a selected compound was investigated by a single operator. With the 
exception of one site, IDRs were similar for both media following single operator analysis. 
Therefore, having and following a standard method, for data collection and analysis will help 
to reduce variability during intra and inter laboratory experiments. 
The observed variability is likely related to an intrinsic variability which can be expected 
between systems and is difficult to reduce further with experimental controls. While the rank 
order for the three lowest solubility compounds was not maintained, the high and low 
solubility compounds were successfully separated according to IDR at the sites. It is 
important that the MEC values are measured using the system on which the IDR will be 
determined.
The data here shows that the SDI can be used in early development work to measure IDR. 
The variability is similar to the μDISS Profiler™. The advantage this system has over others 
is the imaging capabilities. For APIs at risk of, for example, gelling or form changes, this can 
be observed from the videos produced. Powder release from the compact surface or compact 
disintegration can be detected and visualised using the imaging, providing information on the 
behaviour of the API. For the majority of compounds, the two different small-scale IDR 
methods compared here are likely to be suitable. An internal database of knowledge should 
be gathered for allowing comparisons between APIs to make determinations. Further work is 
required to investigate the suitability of the SDI method for high solubility, high absorbance 
drugs.
The current study highlights the challenges associated with determining a seemingly simple 
but important parameter affecting the performance of drug candidates. Variability at and 
between sites is remarkable and should be kept in mind assessing dissolution rate data.
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6 Supplementary Material
Table 5. Mean MEC values for each API in media used.
API Media Mean MEC (M-1 cm-1) (SD/RSD) No. of Sites
FaSSIF 8.43 x 103 (2.27 x 103/27%) 6Bromocriptine mesylate Blank FaSSIF 5.90 x 103 (1.71 x 102/2.9%) 2
FaSSIF 8.29 x 103 (3.04 x 103/37%) 5Carvedilol Blank FaSSIF 9.42 x 103 (4.20 x 103/45%) 5
FaSSIF 2.78 x 102 (7.05 x 101/25%) 5Ibuprofen Blank FaSSIF 2.81 x 102 (5.39 x 101/19%) 6
FaSSIF 1.82 x 104 (5.06 x 103/28%) 6Indomethacin Blank FaSSIF 1.88 x 104 (3.32 x 103/18%) 7
FaSSIF 1.06 x 104 (3.38 x 103/32%) 6Tadalafil Blank FaSSIF 1.22 x 104 (3.24 x 103/27%) 2
FaSSIF 1.16 x 104 (3.75 x 103/32%) 7Valsartan Blank FaSSIF 1.28 x 104 (2.44 x 103/19%) 7
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